Botulinum Toxin and Nerve Block Tested Together for Chronic Migraine
Tests botulinum toxin with a nerve block in adults with chronic migraine headaches.
Plain-language title generated from the registry record
Registry title: Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine
Key facts
- Where
- Al Fayyum, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic migraine. It tests botulinum toxin (OnabotulinumtoxinA) injections together with a greater occipital nerve block, compared with a single treatment.
- Age
- Older than 18 years
- Sex
- Women and men can join
- Disease stage
- Chronic migraine: headache on 15 or more days per month for more than three months, with at least 8 days per month showing migraine features
- Earlier treatment
- Must have been on a stable migraine preventive treatment for at least two months. Cannot have had BoNT-A or a greater occipital nerve block for headache in the previous 3 months.
Main reasons for not taking part
- Known allergy to BoNT-A or local anesthetics
- Neck anatomy problems that make the injections hard or unsafe
- Neuromuscular junction disorders such as myasthenia gravis
- Bleeding disorders or blood thinner treatment that rules out a nerve block
- Pregnancy
Read by machine on 12 November 2026.
Where in Egypt
- Beni-Suef University HospitalAl Fayyum, EgyptContact: Rakia Mohamed Basiouny, neurology residentNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beni-Suef University
- Trial code
- NCT07535723
- Record updated
- 17 April 2026
- Original description
Chronic migraine is a debilitating neurological disorder that significantly affects patients' daily functioning, mental health, and quality of life. Management typically includes acute and preventive treatments, but effectiveness can be limited due to medication overuse or delayed onset of action. OnabotulinumtoxinA injections provide proven long-term preventive benefits, while Greater Occipital Nerve (GON) block offers rapid but short-term relief. Although both treatments are used individually, evidence on the combined effect is limited. This randomized controlled trial aims to evaluate the efficacy and safety of combining OnabotulinumtoxinA injections with GON block, assessing improvements in headache frequency, severity, and patient quality of life compared to single therapy.Read full original descriptionShow less
Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine
Chronic migraine is a debilitating neurological disorder that significantly affects patients' daily functioning, mental health, and quality of life. Management typically includes acute and preventive treatments, but effectiveness can be limited due to medication overuse or delayed onset of action. OnabotulinumtoxinA injections provide proven long-term preventive benefits, while Greater Occipital Nerve (GON) block offers rapid but short-term relief. Although both treatments are used individually, evidence on the combined effect is limited. This randomized controlled trial aims to evaluate the efficacy and safety of combining OnabotulinumtoxinA injections with GON block, assessing improvements in headache frequency, severity, and patient quality of life compared to single therapy.
Inclusion: Diagnosis of chronic migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3): headache occurring on ≥15 days per month for more than three months, with at least 8 days per month exhibiting migraine features. (International Headache Society, 2013); Age > 18 years; Stable preventive migraine regimen for at least two months prior to recruitment.
Exclusion: Prior treatment with BoNT-A or GONB for headache within the previous 3 months; Known hypersensitivity to BoNT-A or local anesthetics; Neuromuscular junction disorders (e.g., myasthenia gravis); Coagulation disorders or anticoagulant therapy that contraindicates nerve block; Significant psychiatric comorbidity that would impair proper pre and post treatment assessment; Co-morbid other; Cervical anatomical abnormalities that hinder proper localization of injection sites or compromise the safety of the procedure; Pregnancy.